OTCMKTS:CYBN Cybin (CYBN) Stock Price, News & Analysis $0.22 -0.02 (-8.39%) (As of 09/5/2024 ET) Add Compare Share Share Today's Range$0.17▼$0.2350-Day Range$0.22▼$0.3252-Week Range$0.17▼$0.74Volume10.08 million shsAverage Volume4.92 million shsMarket Capitalization$89.69 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisAnalyst ForecastsChartEarningsFinancialsHeadlinesOwnershipSEC FilingsStock AnalysisAnalyst ForecastsChartEarningsFinancialsHeadlinesOwnershipSEC Filings Get Cybin alerts: Email Address Ad InvestorPlaceJeff Bezos Just Humiliated Elon MuskThe Next Nvidia? Wall Street legend has just uncovered one tiny Maryland company that could become the next Nvidia. Few in the media are talking about this story yet… but in the next 6 months that’s all they’ll talk about.Go here now for this breaking story. About Cybin Stock (OTCMKTS:CYBN)Cybin Inc., a clinical-stage biopharmaceutical company, focuses on developing psychedelic-based therapeutics. The company's development pipeline includes CYB003, a deuterated psilocybin analog, which is in Phase 1/2a clinical trial to treat major depressive and alcohol use disorders; CYB004, a deuterated dimethyltryptamine, which is in Phase 1 clinical trial for treating generalized anxiety disorders; and CYB005, a phenethylamine derivative, which in preclinical stage to treat neuroinflammation. It has also developed EMBARK, a psychological support model that integrates clinical approaches to promote supportive healing with psychedelic medicine. The company is headquartered in Toronto, Canada.Read More CYBN Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CYBN Stock News HeadlinesSeptember 4 at 8:54 AM | finance.yahoo.comCybin to Participate in the H.C. Wainwright 26th Annual Global Investment ConferenceAugust 30, 2024 | nz.finance.yahoo.comCybin Inc (R7E1.DU)September 6, 2024 | InvestorPlace (Ad)Jeff Bezos Just Humiliated Elon MuskThe Next Nvidia? Wall Street legend has just uncovered one tiny Maryland company that could become the next Nvidia. Few in the media are talking about this story yet… but in the next 6 months that’s all they’ll talk about.August 30, 2024 | nz.finance.yahoo.comCybin Inc (R7E1.MU)July 31, 2024 | markets.businessinsider.comBuy Rating Affirmed for Cybin Amid Advancements in Psychedelic Medicine and Strategic Regulatory ApproachesMay 6, 2024 | finance.yahoo.comCybin Provides Corporate Update and Highlights Upcoming Clinical MilestonesMay 6, 2024 | businesswire.comCybin Provides Corporate Update and Highlights Upcoming Clinical MilestonesApril 18, 2024 | businesswire.comCybin Announces Publication of Research Manuscript in the Journal of Medicinal ChemistrySeptember 6, 2024 | InvestorPlace (Ad)Jeff Bezos Just Humiliated Elon MuskThe Next Nvidia? Wall Street legend has just uncovered one tiny Maryland company that could become the next Nvidia. Few in the media are talking about this story yet… but in the next 6 months that’s all they’ll talk about.April 16, 2024 | businesswire.comCybin Announces Grant of Additional U.S. Patent in Support of its CYB003 Breakthrough Therapy Program for Major Depressive DisorderApril 10, 2024 | businesswire.comCybin to Present at the 2024 Bloom Burton & Co. Healthcare Investor ConferenceApril 10, 2024 | businesswire.comCybin to Present at the 2024 Bloom Burton & Co. Healthcare Investor ConferenceMarch 26, 2024 | investorplace.com3 Penny Stocks That Could Be Multibaggers in the Making: March EditionMarch 19, 2024 | businesswire.comCybin Announces Closing of the Oversubscribed Private Placement of U.S. $150 MillionMarch 18, 2024 | businesswire.comCybin to Present at Public Ventures Discovery Day on March 19th in DallasMarch 15, 2024 | businesswire.comCybin Initiates Phase 2 Proof-of-Concept Study of CYB004 in Generalized Anxiety DisorderMarch 14, 2024 | markets.businessinsider.comCybin’s CYB003 Shows Promise in MDD Treatment, Justifying Buy RatingMarch 14, 2024 | msn.comCybin to begin Phase 3 study for psychedelic drug mid-yearSee More Headlines Receive CYBN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cybin and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/08/2024Today9/06/2024Fiscal Year End3/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Biotechnology Sub-IndustryPharmaceutical Products Current SymbolOTCMKTS:CYBN CUSIPN/A CIK1833141 Webwww.cybin.com Phone(866) 292-4601FaxN/AEmployees50Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($0.20) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-35,930,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-93.17% Return on Assets-84.68% Debt Debt-to-Equity RatioN/A Current Ratio2.61 Quick Ratio2.61 Sales & Book Value Annual Sales$680,000.00 Price / Sales131.90 Cash FlowN/A Price / Cash FlowN/A Book Value$0.19 per share Price / Book1.15Miscellaneous Outstanding Shares410,855,000Free Float170,213,000Market Cap$89.69 million OptionableNot Optionable Beta0.42 13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.Get This Free Report Key ExecutivesMr. Eric So L.L.B. (Age 48)Co-Founder, President & Executive Chairman Comp: $455.15kMr. Douglas L. Drysdale (Age 54)Chief Executive Officer Comp: $608.45kMr. Paul Glavine (Age 35)Co-Founder, Chief Growth Officer & Director Comp: $455.15kMr. Greg Cavers (Age 53)Chief Financial Officer Comp: $240.12kMr. Aaron BartloneChief Operating OfficerMr. John Kanakis (Age 44)Co-Founder Comp: $698.3kDr. Alex L. Nivorozhkin Ph.D. (Age 64)Chief Scientific Officer Ms. Lori ChallengerChief Compliance, Ethics & Administrative OfficerMr. Gabriel Fahel (Age 48)Chief Legal Officer & Corporate Secretary Sara Brittany SomersetChief Communications OfficersMore ExecutivesKey CompetitorsFate TherapeuticsNASDAQ:FATEXeris BiopharmaNASDAQ:XERSZevra TherapeuticsNASDAQ:ZVRAAquestive TherapeuticsNASDAQ:AQSTLexeo TherapeuticsNASDAQ:LXEOView All Competitors CYBN Stock Analysis - Frequently Asked Questions How have CYBN shares performed this year? Cybin's stock was trading at $0.41 at the start of the year. Since then, CYBN shares have decreased by 46.8% and is now trading at $0.2183. View the best growth stocks for 2024 here. How were Cybin's earnings last quarter? Cybin Inc. (OTCMKTS:CYBN) posted its quarterly earnings results on Thursday, August, 8th. The company reported ($0.01) earnings per share for the quarter. How do I buy shares of Cybin? Shares of CYBN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (OTCMKTS:CYBN) was last updated on 9/6/2024 by MarketBeat.com Staff From Our PartnersThis Crypto Is Set to Explode in AugustWhen cryptos take a hit, the mom and pop investors run for the hills. But the top investors keep buying wit...Crypto 101 Media | SponsoredPre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A inv...Mode Mobile | SponsoredThese 2 simple sentences turn every Friday into payday?Most people have never heard of Jim Fink. Behind his humble demeanor and insistence on personal privacy... ...Investing Daily | SponsoredThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase,...Deal Maker | SponsoredJeff Bezos Just Humiliated Elon MuskThe Next Nvidia? Wall Street legend has just uncovered one tiny Maryland company that could become the next...InvestorPlace | SponsoredThe death of Nvidia?Today, I’m warning of another looming catastrophe. Only this time, it’s not in pot stocks, cryptos, or U.S....Porter & Company | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredWhat is Nvidia’s New $1 Trillion SuperProject?Taiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as ...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cybin Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cybin With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CYBN Stock Alerts